Meridian Co., Ltd. announced that it has reached a major milestone in the execution of its strategic business plan of establishing a significant role in the 9 billion dollar aesthetic market in North America. The company filed a Premarket Notification, or a 510(k) with the
US FDA, to allow it to market the non-invasive Lipo-Laser device for the indication
of body contouring and temporary reduction in the appearance of cellulite. Using
cutting edge laser technology intended specifically for this use, this device
will be the first of its kind that would be cleared by the US FDA.
Market
Wire
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
Theradiag Snags CE Mark for Biotherapy Monitoring Analyzer
The i-Track10 can be integrated into laboratory automation systems and features random access analysis and continuous loading capabilities.
Petition Urges FDA, DEA to Classify Tramadol as a Schedule II Controlled Substance
The DEA classified tramadol as a Schedule IV controlled substance in 2014.
FDAnews Device Daily Bulletin
MERIDIAN ANNOUNCES 510K SUBMISSION TO THE FDA FOR THE LIPO-LASER
June 22, 2006
